Overview

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Status:
Terminated
Trial end date:
2017-12-19
Target enrollment:
Participant gender:
Summary
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT. Briefly, a subject will receive a light-sensitive drug, called Photofrin®, the day before a tumor removal surgery. The next day, after the tumor is removed, red light from a laser will be shone into the tumor cavity through a light-diffusing sphere. This light will activate the photosensitizer, and possibly kill any tumor cells that may be left. We plan to measure how long the subject may go without a new tumor regrowth, and overall how long subjects survive. We will compare these results to typical results to see if we are seeing any improvements. Objective: To define the antitumor activity of Photofrin® and laser light activation within the confines of a Phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
Harry T Whelan, MD
Collaborator:
Pinnacle Biologics Inc.
Treatments:
Dihematoporphyrin Ether
Hematoporphyrin Derivative
Trioxsalen